High-dose cytosine arabinoside-associated pancreatitis.
Thirty patients with leukemia and lymphoma have been treated at our institution with high doses of cytosine arabinoside (Ara-C). Gastrointestinal symptoms were frequent after therapy, and 6 of the 30 patients had severe abdominal pain. Of the six, two had pancreatitis; two had normal amylase and lipase determinations; and in two, neither amylase nor lipase levels were determined. The two patients with pancreatitis are presented because this complication of high-dose Ara-C therapy has not been described. The authors conclude that pancreatitis can follow high-dose Ara-C chemotherapy and that patients with abdominal pain following this treatment be evaluated for pancreatitis.
R F
RF
Siemers
W R
WR
Friedenberg
R G
RG
Norfleet
D000328:Adult; D000681:Amylases / Q000097:blood; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007527:Isoenzymes / Q000097:blood; D007938:Leukemia / Q000188:drug therapy; D008049:Lipase / Q000097:blood; D008223:Lymphoma / Q000188:drug therapy; D009325:Nausea / Q000139:chemically induced; D010146:Pain / Q000139:chemically induced; D010195:Pancreatitis / Q000139:chemically induced* / Q000201:enzymology; D012189:Retrospective Studies
D007527:Isoenzymes; D003561:Cytarabine; D008049:Lipase; D000681:Amylases